<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03466463</url>
  </required_header>
  <id_info>
    <org_study_id>GNT-012-CRIG</org_study_id>
    <nct_id>NCT03466463</nct_id>
  </id_info>
  <brief_title>Gene Therapy for Severe Crigler Najjar Syndrome</brief_title>
  <acronym>CareCN</acronym>
  <official_title>A Phase I/II, Open Label, Escalating Dose Study to Evaluate Safety and Efficacy of an Intravenous Injection of GNT0003 (AAV Vector Expressing the UGT1A1 Transgene) in Patients With Severe Crigler-Najjar Syndrome Requiring Phototherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genethon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genethon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/2, multinational, open-label, escalating-dose study to evaluate the safety
      and efficacy of an intravenous infusion of GNT0003 in patients with Crigler-Najjar aged ≥10
      years and requiring phototherapy. Patients will received a single administration of GNT0003
      and will be followed for safety and efficacy for 1 year.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2018</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events / Serious Adverse Events (Safety) : All Treatment Emergent Adverse Events, all Serious Adverse Events</measure>
    <time_frame>29 months</time_frame>
    <description>Incidence of AE/SAE evaluated by changes in laboratory parameters, vital signs, physical examination, reported from baseline to each visit, evaluated for each dose and for the study as a whole. Clinically relevant abnormal findings on Laboratory values, Vital Signs, Physical findings will be reported as Adverse Events.
Incidence and Severity of Adverse Events for each body system will be presented for each dose level and summarized overall.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Decrease of total Serum bilirubin level after interruption of daily phototherapy (Efficacy)</measure>
    <time_frame>14 months</time_frame>
    <description>Serum total bilirubin ≤ 300 µmol/L, 7 days after interruption of daily phototherapy occuring at week 16 after the administration of GNT0003.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>29 months</time_frame>
    <description>Scale 36-Item Short Form Survey (SF-36 Heath Survey for adults) - score range : 0 worse value : - better value (more favorable health state): 100. Scores represent the percentage of total possible score achieved. The scores from those questions that address each specific area of functional health status (STEP II chart) are then averaged together, for a final score within each of the 8 dimensions measured. (eg pain, physical functioning etc.). Outcome measure : change of quality of Life from baseline to Week 24 and week 48 (after IMP administration).
Scale 10- Item Short Form Survey (SF-10 Heath Survey for children) - score range : 1 (worse value) to 6 (more favorable health state). : 100 The SF-10 Health Survey for Children is a parent-completed survey that contains 10 questions adapted from the Child Health Questionnaire. Outcome mesure : change of quality of Life from baseline to Week 24 and week 48 (after IMP administration).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">17</enrollment>
  <condition>Crigler-Najjar Syndrome</condition>
  <arm_group>
    <arm_group_label>GNT0003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses of the IMP assessed in a dose escalation, open-label, phase 1/2 study</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>GNT0003</intervention_name>
    <description>Intravenous infusion, single dose</description>
    <arm_group_label>GNT0003</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with severe Crigler-Najjar syndrome resulting from a molecular confirmation
             of mutations in the UGT1A1 gene and requiring phototherapy

          -  Male or female at least 9 years at the date of signature of informed consent

          -  Patient able to give informed assent and/or consent in writing

        Exclusion Criteria:

          -  Patients who underwent liver transplantation

          -  Patients with chronic hepatitis B or C

          -  Patients infected with Human immunodeficiency virus (HIV)

          -  Patients with significant underlying liver disease

          -  Patients with significant encephalopathy

          -  Participation in any other investigational trial during this trial

          -  Patients unable or unwilling to comply with the protocol requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Genethon Clinical Development Department</last_name>
    <phone>00 33 (0)1 69 47 10 32</phone>
    <email>clinical_development@genethon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopital Antoine BECLERE</name>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00 33 (0)1 45 37 42 72</phone>
      <email>philippe.labrune@abc.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe LABRUNE, MD,PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Papa Giovanni XXIII</name>
      <address>
        <city>Bergame</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>00390352674959</phone>
      <email>ldantiga@asst-pg23.it</email>
    </contact>
    <investigator>
      <last_name>Lorenzo D'Antiga, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Federico II</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00390816132361</phone>
      <email>brunetti@tigem.it</email>
    </contact>
    <investigator>
      <last_name>Nicola Brunetti-Pierri, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0031-641476782</phone>
      <email>u.h.beuers@amc.uva.nl</email>
    </contact>
    <investigator>
      <last_name>Ulrich Beuers, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2018</study_first_submitted>
  <study_first_submitted_qc>March 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2018</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crigler-Najjar</keyword>
  <keyword>Adeno Associated Virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Crigler-Najjar Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

